Atossa Therapeutics to Present at the Maxim Growth Summit 2025

Core Insights - Atossa Therapeutics is actively engaging with investors by participating in the Maxim Growth Summit on October 22–23, 2025, where the CEO will be available for one-on-one meetings [1][3] - The company focuses on developing innovative therapies for breast cancer, emphasizing disciplined capital allocation to support future regulatory submissions and commercialization [4][6] Company Overview - Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker ATOS, dedicated to addressing significant unmet needs in breast cancer treatment and prevention [4] - The company's strategy includes concentrating resources on programs that can lead to regulatory submissions and potential market entry [6] Investor Engagement - Prospective and existing investors are encouraged to visit Atossa's website for the latest presentations, SEC filings, and to sign up for email alerts [3] - The company believes that its disciplined capital allocation and clear clinical objectives create an attractive investment opportunity for long-term value creation [6]